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INTRODUCTION
Flt3 is a member of the type III receptor tyrosine
kinase family ; murine and human analogs share
86% structural homology. Fms-like tyrosine kinase
3 ligand (FL), a hematopoietic growth factor, is a
specific ligand for Flt3. FL is widely expressed in
both murine and human tissues. Murine and hu-
man FL are 75% homologous, and both ligands are
fully active in cells bearing either murine or human
receptors (1). FL plays an important role in the pro-
liferation, survival, and differentiation of early murine
and human hematopoietic precursor stem cells.
The majority of common lymphoid precursors ex-
press high levels of Flt3 and are highly efficient pre-
cursors of dendritic cells (DCs). FL is a growth fac-
tor for hematopoietic progenitors, which also pro-
motes the growth of DCs. Administration of FL to
mice results in increased numbers of functionally
active DCs in the bone marrow, gastrointestinal lym-
phoid tissue, liver, lymph nodes, lung, peripheral
blood, peritoneal cavity, spleen, and thymus (1).
Further, administration of FL to healthy human vol-
unteers is known to markedly elevate the number
of circulating DCs (2). Following FL administration,
an increase in the number of both myeloid and
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lymphoid type DCs in mice and humans has been
noted ; moreover, impressive antitumor effects have
been induced in several murine models (3-6). It
was shown that administration of either tumor cells
transfected in vitro with Flt3L vectors or soluble
Flt3L fusion protein in a high dose can enhance
host antitumor immunity (7). DCs are powerful
antigen-presenting cells (APCs) that show a re-
markable capacity to stimulate antigen-specific T-
cell responses. In vitro and in vivo antigen-pulsed
DC can directly sensitize T-cells and stimulate the
development of both protective and therapeutic anti-
tumor immune responses. Several clinical trials have
been initiated to evaluate the efficacy of DC-based
immunotherapies in cancer (1).
FL has distinct effects on the kinetics of recon-
stitution of DCs and natural killer (NK) cells with
potential implications for the modulation of immune
responses (4). NK cells play an important role in
the activity of FL-NK depletion results in antitumor
activity of FL. Hung et al. (5) reported that intrad-
ermal delivery (gene gun) of a recombinant chimera
of FL in tumor-free animals, linked to a model of
antigen increased the frequency of antigen-specific
CD8+ T cells. Lynch et al. (6) reported that FL-
induced fibrosarcoma regression appeared to be
specifically mediated, by CD8+ cells.
Previous studies have shown that particle-medi-
ated transfection is an efficient method of non-viral
gene transfer. It has been shown that the gene gun
can provide a high level of gene expression in a
wide variety of cell types, tissues, and mammalian
species (8). The particle-mediated method for gene
delivery using a gene gun utilizes a shock wave to
accelerate DNA-coated gold particles into target
cells or tissues. Rakhmilevich et al . showed that
IL12 cDNA transfer into the tumor by using a gene
gun could achieve IL12 expression in the skin sur-
rounding the tumor, causing regression of the es-
tablished tumor (9). However the effects on tumor
growth by the particle-mediated transfer of FL was
not reported. In this study, we studied the suppres-
sive effect of gene gun-mediated transfer of FL in
a murine model.
MATERIALS AND METHODS
This study was performed in accordance with the
guidelines for animal experimentation of Tokushima
University.
Mice
Female 8 -week -old C57BL/6 mice were pur-
chased from Charles River Laboratories. The ani-
mals were housed in a pathogen-free animal facil-
ity, 5 mice per cage, under controlled conditions of
temperature and humidity.
Tumor cell lines
MCA205 methylcholanthrene-induced fibrosar-
coma cells were kindly provided by the University
of Pittsburg. They were maintained in an RPMI me-
dium supplemented with 10% heat-inactivated fetal
bovine serum, 2 mM L-glutamine, 100 U/mL peni-
cillin, 100 μg/mL streptomycin, 0.1 mM nonessen-
tial amino acids, and 1 mM sodium pyruvate.
Tumor models
Mice were injected intradermally on day 1 with
1105 MCA205 cells in 100 μL saline into a shaved
abdominal area. The induced tumors were meas-
ured two times a week with calipers. The tumor size
represents the product of two perpendicular diame-
ters. For in vivo experiments, 5 mice per group were
routinely used. We used MCA-induced fibrosar-
coma according to the previous paper (6).
Preparation of plasmid DNA
The plasmid pNGVL-hFLex contains the gene for
a secreted form of human FLT3 ligand. We used
pNGVL as a control vector. The plasmid pNGVL-
hFLex was kindly provided by the National Gene
Vector Laboratory of the University of Michigan
(NGVL-UM). The plasmids were amplified in
Escherichia coli and purified using the EndoFree
Maxi Kit (Qiagen, Japan) according to the manu-
facturer’s instructions.
Gene gun-mediated DNA transfer
Gene gun DNA transfer was performed with a
hand-held, helium-driven Helios gene delivery sys-
tem (Bio-Rad Lab). Plasmid DNA was precipitated
onto gold particles with a 1.6-μm average diameter.
Overall, 100 μL of the plasmid DNA was coated on
50 mg of gold particles. The DNA-coated gold parti-
cles (1 μg DNA/bullet) were delivered to the mouse
skin overlying and surrounding the target tumor
with a discharge pressure of 300-400 psi on days 4,
5, 7, 8, 10, 11, 13, 14, 16, and 17 after tumor implan-
tation (Figure 1). Gene therapy was performed ten
times on the basis of the previous report (1).
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Expression of FL mRNA in the tumor by RT-PCR
On day 18 after tumor implantation, mice were
sacrificed and the total mRNA was extracted from
the tumor with the EASYPrep RNA kit (TAKARA,
Japan). The first-strand cDNA synthesis was per-
formed with SuperScriptTM III First-Strand Synthesis
System (Invitrogen, Japan). cDNA was PCR-ampli-
fied using TAKARA Ex Taq (TAKARA) and previ-
ously published primers (sense, 5’ -ACA ACC TAT
CTC CTC CTG CTG-3’ ; antisense, 5’ -GGC ACA
TTT GGT GAC AAA GTG-3’). The housekeeping
gene GAPDH (sense, 5’ -CAG GTT GTC TCC TGC
GAC TT-3’ ; antisense, 5’-CTT GCT CAG TGT CCT
TGC TG-3’) was used as a control. PCR amplifica-
tion consisted of an initial denaturation step at 94
for 4 min, followed by 30 cycles at 94for 1 min,
annealing at 65for 1 min, and extension at 72
for 1 min.
Immunohistochemistry
The freshly removed tumor specimens were
placed in an embedding medium (Tissue Tek OTC
compound, SAKURA), snap-frozen in liquid nitro-
gen, and stored at -80. For the staining of cell dif-
ferentiation markers, 5-μm thick frozen tissue sec-
tions were cut in a cryostat, air-dried, and fixed in
acetone for 10 min. The following primary mAbs
were used : rat anti -mouse MHC Class II, CD4,
CD8a (eBioscience, USA), CD3 (BD Bioscience-
Pharmingen, USA), and hamster anti-mouse CD11c
(eBioscience). Each primary Ab was applied for 30
min at room temperature. After two washes in PBS,
the sections were incubated with the biotinylated
secondary rabbit anti-rat IgG Ab or goat anti- ham-
ster IgG Ab for 30 min, and then developed with
the VectastainElite ABC kits and Vector DAB sub-
strate (Vector Laboratories, USA). After substrate
development, the sections were counterstained with
hematoxylin. We counted the number of CD11c+,
CD4+, CD8+, and CD3+ cells in 10 high power fields.
fluorescence-activated cell sorter (FACS)
Tumor cells from control mice or from mice
treated with FL therapy were obtained on day 18
after tumor implantation. The tumor was harvested
and single cell suspensions were prepared by me-
chanical dissociation and collagenase treatment. The
cells were stained with FITC-conjugated rat-anti-
mouse CD80 monoclonal antibody and PE-conju-
gated rat-antimouse IA-b monoclonal antibody for
(BD Bioscience-Pharmingen) for 60 min at 4.
Propidium iodide (2 μg/mL) was added to stain
dead cells, which were subsequently excluded from
analysis. Analysis was performed on a Becton
Dickinson FACScan with CELLQuest software
(Becton Dicknson Immunocytometry System,
Mountain View, CA). Data were collected for 10,000
events/sample.
Statistical analysis
All data expressed as meanS.D. are represen-
tative of at least two different experiments. Statisti-
cal analysis was performed using the unpaired two-
tailed Student’s test. The statistical analysis regard-
ing FACS was performed by chi-square test.
RESULTS
A therapeutic effect mediated by gene gun
To study the anti-tumor effect of gene gun-me-
diated pNGVL-hFLex transfer in the treatment
model, we treated a total of 10 mice in dependent
experiments. As shown in Figure 2, gene-gun me-
diated transfer of pNGVL-hFLex significantly inhib-
ited the growth of MCA205 tumor cells (P=0.011).
Figure 1. Experimental plan for FL-transfer and tumor challenge.
Experimental setting. Mice were injected i.d. with 1105 cells of MCA205. The DNA-coated gold particles (1 μg DNA/bullet) were
delivered to the mouse skin overlying and surrounding the target tumor with a discharge pressure of 300-400 psi on days 4, 5, 7, 8,
10, 11, 13, 14, 16 and 17 after tumor implantation.
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FL expression in the tumor
To examine FL expression, mRNA extracted from
the tumor was subjected to RT-PCR analysis. As
shown in Figure 3, FL mRNA was expressed in the
pNGVL-hFLex-transfected tumor but not in the con-
trol vector-transfected tumor.
To clarify the immune reaction at the tumor site
by FL transfer with gene gun, we determined the
number of tumor-infiltrating cells by immunohisto-
chemical analysis. Tumors from both control and
treated mice were analyzed 18 d after implantation
using immunohistochemical techniques. FL transfer
increased the number of CD11c+ DCs in the tumor
tissues (94/HPF vs 8/HPF). As shown in Figure 4,
we also noted a increase in both CD4+, CD8+, and
CD3+ cells in the tumors obtained from FL-treated
animals as compared with those from the controls
(86/HPF vs 26/HPF, 97/HPF vs 12/HPF, 84/HPF
vs 32/HPF).
To investigate the impact of FL on DCs in vivo ,
we examined the number of DCs in the tumor
using flow cytometry. As shown in Figure 5, FL-
transfected mice exhibited significantly higher num-
bers of CD80+ MHC II cells compared to mice trans-
fected with the control vector. FL therapy markedly
increased the percentage of I-Ab+CD80+ cells were
significantly increased (3.6% vs. 11.5% : p0.05) in
the tumor. CD80+ cells represent a typical pheno-
typic marker of DC maturation. It showed that ma-
ture DC located in the tumor.
Figure 2. Administration of FL inhibited the tumor growth in MCA205.
Mice were injected i.d. with 1105 cells of MCA205. The DNA-coated gold particles(1 μg DNA/bullet) were delivered to the mouse
skin overlying and surrounding the target tumor with a discharge pressure of 300-400 psi on days 4, 5, 7, 8, 10, 11, 13, 14, 16, and 17
after tumor implantation. For each tumor, 2 independent groups of mice were used in the experiment (total n=10 mice). One group
was boosted with a plasmid including the FL gene (■). The other group was boosted with a control vector (●). Mean tumor areas
for the FL therapy group and the control group are shown. Scale bar=SD. The difference between these 2 curves was statistically
significant (P=0.011).
Figure 3. RT-PCR analysis of FL mRNA expression in the tu-
mor after gene transfer.
Lanes 1, 2 : Tumors transfected with FL
Lanes 3, 4 : Tumors transfected with control vector
Lanes 5, 6 : plasmid pNGVL-hFLex alone
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DISCUSSION
Gene gun therapy is one of several non-viral
transfection methods that achieve good, but tran-
sient, expression of transfected genes (10). A pre-
vious paper has described that despite low levels
of transgenic IL-12 administered via the gene gun,
complete regression of established tumors was
achieved in mice. Transfer of IL-12 cDNA into epi-
dermal cells overlying an implanted intradermal tu-
mor resulted in detectable levels (266.027.8 pg)
of the transgenic protein at the skin tissue treatment
site (9).
The interaction between plasmid DNA and DCs
in vivo is incompletely understood. Stoecklinger A
et al described that gene gun immunization is ca-
pable of inducing immune reactions independently
of epidermal Langerhans cells (10). And gene gun
therapy induced skin DC maturation and migration
of transfected DC to draining lymph nodes. A small
amount of antigen could be traced to the draining
lymph nodes in mice immunized with the gene gun.
Gaffal et al showed that CD8+ cells stimulated by
the gene gun differ phenotypically and function-
ally from those stimulated by live virus (11). They
showed that gene gun stimulated a predominantly
regional CD8+ Tcell response and is less effective
than intracutaneous injection of virus-transduced
DC.
In this study, administration of FL by a gene gun
showed inhibition of tumor growth in a murine
model of intradermal tumors. We demonstrated an
increase in the number of DCs within tumor with
Figure 4. Immunohistochemical staining of CD11c+ CD8,
CD4, and CD3 cells in the local tumor site on day 18 after tu-
mor implantation. (FL therapy : A, C, E, and G) (control : B, D,
F, and H).
Figure 5. Flow cytometry for CD80 and I-Ab expression in local tumor.
DC expansions induced by Flt -3L (FACS analysis) ; tumors of mice treated with control vectors (a) or pNGVL-FL(b) were analyzed
by flow cytometry for CD80 and I-Ab expression. Negative controls included staining with the corresponding isotype for each Ab
and staining with the secondary Ab alone. Positive controls included immunostaining of known positive tissues. All sections were
lightly counterstained with hematoxylin.
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an increased expression of CD80. After gene-ther-
apy, not only the number of CD11c+ DCs but also
those of CD4+, CD8+, and CD3+ cells increased. The
recruitment of cytotoxic and helper T lymphocytes
in the tumor may play a role in the suppressive
effects of FL transfer. Taken together, our data sug-
gest that treatment of tumor-bearing mice by intra-
tumoral administration of pNGVL-hFLex gene using
the gene gun results in significant inhibition of tu-
mor growth in vivo . Overall, treatment with DCs
transduced with FL showed an result in a decrease
in the MCA205 tumor size. In the present study,
we found that tumor growth was inhibited by FL
treatment but the suppressive effect was not com-
plete. Hou et al showed that administration of sol-
uble FL protein and local injection of adenovirus
with insert of gene encoding extracellular domain
of mouse Flt3L was effective in eliciting host im-
mune responses, which is able to cure tumors with
a small size (12).
The in vivo delivery of the FL transgene has been
suggested as an alternative to the injection of the FL
protein. Shimano et al . reported that FL gene trans-
fer using IVE (in vivo electroporation) could mobi-
lize and promote the maturation of DCs in vivo (13).
It has been already reported that administration of
FL protein can induce an increase in both lymphoid-
related DCs induced to enhance Th1-like responses
and myeloid-related DCs that enhance mixed Th1-
type responses in murine models (3). The cytokine
for the development of the CD8+ DC subset is FL
which has major influences on the development of
inflammatory and migratory DCs (14). It was shown
that administration of soluble FL protein and local
injection of Ad-mFL was effective in eliciting host
immune response, which is able to cure tumors with
a small size (7). Leading to a high production of
mFlt3L proteins in association with accumulation
of DCs, NK cells and lymphocytes in local tumor
regions. In association with the immune responses,
DCs and NK cells recruitment to the tumor oc-
curred, which may facilitate tumor necrosis and
enhance tumor antigen presentation.
We showed here that FL therapy increased the
number of DCs and T cells in the tumor site and
delayed the speed of tumor growth. It did not com-
pletely eliminate the tumor. Our data suggest that
DNA vaccination via the gene gun represents a po-
tent regimen for DNA administration. We suggest
that this method may become useful in immunother-
apy using DCs. In this study, we performed FL ther-
apy using an in vivo gene gun in order to effectively
mobilize DCs in situ . We considered that the use
of other cytokines and/or immunomodulatory mole-
cules together with FL might offer attractive per-
spectives for immunotherapy.
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